Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the presentation of data from a real-world survey of patients taking AUSTEDO XR extended-release tablets. Patients taking AUSTEDO XR reported increased social and emotional well-being as a result of movement reduction, and high overall satisfaction with AUSTEDO XR. The data were presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025 in San Diego, California. Key results revealed that both groups: stated their uncontrollable movements were very much, much, or minimally improved once treated with AUSTEDO XR; strongly agreed or agreed that since starting AUSTEDO XR their reduction in movements led to more comfort in social settings and improved emotional well-being; liked that their provider could adjust their dose; reported it was easy to take AUSTEDO XR; reported overall satisfaction with AUSTEDO XR
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva preesents 10 posters from its schizophrenia medicines portfolio
- Riot, D-Wave, AmEx, Lowe’s, Teva: Stock Shake-Up!
- Teva’s emrusolmin granted U.S. FDA Fast Track designation
- Teva announces FDA approval, launch of Generic Saxenda
- Acadia Pharmaceuticals names Katcheves Chief Business and Strategy Officer